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Stage at diagnosis and survival from cancer vary according to where people live, suggesting some may have delays in diagnosis. The
aim of this study was to determine if time from presentation to treatment was longer for colorectal and breast cancer patients living
further from cancer centres, and identify other important factors in delay. Data were collected on 1097 patients with breast and 1223
with colorectal cancer in north and northeast Scotland. Women with breast cancer who lived further from cancer centres were
treated more quickly than those living closer to cancer centres (P¼0.011). Multilevel modelling found that this was largely due to
them receiving earlier treatment at hospitals other than cancer centres. Breast lump, change in skin contour, lymphadenopathy, more
symptoms and signs, and increasing age predicted faster treatment. Screen detected cancers and private referrals were treated more
quickly. For colorectal cancer, time to treatment was similar for people in rural and urban areas. Quicker treatment was associated
with palpable rectal or abdominal masses, tenesmus, abdominal pain, frequent GP consultations, age between 50 and 74 years,
tumours of the transverse colon, and iron medication at presentation. Delay was associated with past anxiety or depression. There
was variation between general practices and treatment appeared quicker at practices with more female general practitioners.
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For all cancers, stage at diagnosis is important for survival. For
example, 5-year survival from colorectal cancer varies from 87%
for tumours limited to the bowel wall (Dukes A) to 15% for
advanced tumours in whom only palliative resection is undertaken
(McArdle and Hole, 2002). There is concern that the relatively poor
survival rates from cancer reported in the United Kingdom may be
caused by relatively late stage disease at diagnosis and that this
may reflect delays before treatment (Coebergh et al, 1998; Gatta
et al, 2000). Within the United Kingdom, chances of both early
diagnosis of and survival from cancer vary according to where
people live. In Scotland, for several common cancers, increasing
distance from cities with cancer centres is associated with more
advanced disease at diagnosis and poorer early survival (Campbell
et al, 2000, 2001). This accords with studies in Europe and the
United States (Liff et al, 1991; Launoy et al, 1992).
The principle that all patients wherever they live should have
access to a uniformly high quality of care to ensure the best
possible survival rates was laid down by the Expert Advisory
Group on Cancer in England and Wales and endorsed in Scotland
(EAGC, 1995; SCCAC, 1996). Recognising the importance of stage
at diagnosis, the cancer plans have set targets in an attempt to
speed up time to treatment (NHS, 2000). Little is known, however,
about factors that influence delay in diagnosis, nor how they affect
delay at the various levels where it can occur. Delays in diagnosis
can occur before presentation (patient delay) or between initial
presentation and treatment (provider delay). This study aimed to
determine for patients with breast and colorectal cancer if the time
between first presentation and specialist treatment was longer for
patients who lived further from cancer centres than for patients
who lived nearby, and to discover which other patient, general
practice and secondary care characteristics were associated with
time to treatment.
METHODS
People resident in the Grampian, Tayside or Highland Health
Board areas of Scotland who were diagnosed with a first primary
tumour of colorectal or breast cancer (female) between 1 January
1997 and 31 December 1998 were identified from the Scottish
Cancer Registry (Brewster et al, 1997). Their names, dates of birth
and death, sex, postcodes and health boards of residence at time of
diagnosis, cancer sites, practices registered with at time of
diagnosis, incidence dates and histories of previous cancers were
obtained from the registry. Information on dates of death had been
provided by the General Register Office (Scotland) and linked with
the cancer registration record by record linkage at the Information
and Statistics Division of the NHS in Scotland (Kendrick and
Clarke, 1993). Cases that were duplicates, or could not be matched
to 1991 census output areas, or were not allocated to practices in
the study areas were excluded.
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lPermission was requested from all general practitioners in the
study area with eligible patients to review medical records. Patients
who had moved from practices were excluded from the study.
Records of deceased patients were requested from the Practitioner
Services Division of the NHS in Scotland. Data collected from
medical records between May 2001 and May 2002 included
presenting symptoms and clinical signs, dates and places of
consultations, referral route and destination, date of first treatment
(surgery, radiotherapy, chemotherapy or hormone therapy) and
previous history (cancer, breast/bowel comorbidity, breast/bowel
investigations with benign results, anxiety, depression, iron
medication and smoking status).
A ‘2-year rule’ was used to reduce the likelihood of recording
symptoms unrelated to the diagnosis of cancer. Working back in
time from the date the cancer was diagnosed, the date was
recorded of the first entry in the GP consultation notes of a
relevant sign or symptom that appeared more than 2 years after
any previous such sign or symptom. The list of eligible symptoms
and signs was collated mainly from SIGN guidelines (SIGN, 1998,
2003).
Aggregated data from the 1991 Census were used to calculate
distances to cancer centres and deprivation categories (each
containing a fifth of the population of Grampian, Tayside and
Highland) at the smallest level possible, the output area (Campbell
et al, 2000, 2001). These were matched to postcodes of residence.
Information on practice list sizes, and number and sexes of
partners in a practice was obtained from an Information and
Statistics Division database of Scottish general practitioners.
Finally, information about the type of out of hours provision
and waiting times for patients to get an appointment with
the doctor of their choice was obtained from staff at practices
visited.
Data were managed using Microsoft Access. Descriptive analyses
were conducted using SPSS for Windows release 11 and multilevel
modelling using MlwiN (Leyland and Goldstein, 2001). Data for
breast and colorectal cancer were analysed separately. Our
outcome was time from first presentation with suspicious
symptoms or signs to first treatment. Our main independent
variable (and the subject of our a priori hypothesis) was distance
to a cancer centre, which was measured as the straight-line
distance from the grid reference of output area of residence
centroid (from Census data) to the nearest cancer centre (from the
postcode directory) (Campbell et al, 2000, 2001). We also
investigated relationships with time to treatment for multiple
symptoms and variables – these analyses should be considered
exploratory with statistical significance indicated for Po0.002.
In initial univariate analyses, times between presentation and
treatment were highly skewed and so were log transformed to
achieve a Normal distribution and have been converted back to
geometric means and 95% confidence intervals for presentation.
This initial analysis has limitations, however, because it excludes
patients who were not treated, and does not take account of other
significant factors or the structure of the data in four levels –
patient, general practice, hospital of first referral and health board.
In further analysis, multilevel modelling was employed using
binary outcomes for delay (430 days for breast cancer and 490
days for colorectal cancer) to prevent any bias that might have
occurred had those who were not treated been excluded. These cut
points were defined a priori as close to median expected delays and
so results are presented in terms of odds ratios for delay along with
95% confidence intervals. All variables were considered in the
multiple logistic regression models as all were considered to be
clinically important. Initially, variables with Po0.10 (univariately)
were entered together and all other variables were added
individually and assessed at the conventional 5% level. Finally, a
stepwise procedure was performed and compared with the final
model for differences. All final models were assessed for extra-
binomial variation.
Our proposed sample size was 2000 (1000 each with breast
and colorectal cancer). Allowing for an attrition rate of 10–20%,
this was calculated to have 80% power to detect an absolute
difference of 10% in the proportions of cases waiting more than
30 days (breast cancer) or 90 days (colorectal cancer) for
specialist treatment at the 5% significance level in two group
comparisons. Ethical approval for the study was sought and
obtained from Grampian, Tayside and Highland Research Ethics
Committees.
RESULTS
There were 1358 eligible people with breast cancer and 1457 with
colorectal cancer (Figure 1). Of 217 general practices with live
patients in the study area, 196 (90%) responded and 187 (86%)
agreed to case notes review. The 218 (8%) live patients from
practices not agreeing were omitted from the study, along with 143
(5%) who were no longer on their original general practice list, 111
(4%) deceased patients whose notes were unobtainable, and 23
(o1%) for various administrative reasons (principally case notes
unobtainable at practice visits). General Practitioner medical
records were reviewed for 1097 (80.8%) breast cancer cases of
which 1069 had a time from presentation to treatment and 1223
(83.9%) colorectal cancer cases, of which 1071 had a time from
presentation to treatment. The main reason for no time to
treatment was death before treatment. There were few important
differences in available characteristics of patients whose notes were
and were not reviewed, but those not reviewed tended to have been
younger (mean age 63 vs 67 years) and alive at the start of the
study (79 vs 61%).
Breast cancer
The geometric mean for time from presentation to treatment
was 42 days (95% confidence interval 40–45). On univariate
analysis, patients living further from cancer centres tended to be
treated more quickly than those living nearby – the fastest time
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Figure 1 Study profile.
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lof 36 days (30–42) was for people between 38 and 57km
away (Table 1). Older patients were treated more quickly
and several organisational variables appeared to be important,
but deprivation was not a significant factor. Time to treatment
varied significantly according to presenting symptoms – it
was fastest for those with bone pain or ulcerating or fungating
lesions and slowest for those with bloody nipple discharge
(Table 2). Increasing numbers of symptoms at presentation
predicted faster treatment, but asymptomatic patients (predomi-
nantly detected by screening) were also treated quickly. Treatment
was slower for those with previous benign investigations or benign
breast disease.
When variables were assessed in a multilevel model, variation
was found at individual and hospital of first referral levels, but not
general practice or health board (Table 3). The main factors
associated with odds of treatment before 30 days were clinical, but
the number of symptoms that predicted faster treatment
condensed to three – breast lump, change in skin contour and
regional lymphadenopathy. Again, patients with no symptoms
(detected by screening) were treated quickest, but excluding
them, treatment was quicker for patients with more symptoms.
Only one organisational variable remained significant: treatment
was faster for patients referred to noncancer centre hospitals
(other general hospitals and community hospital outreach clinics)
than for those referred to cancer centres and fastest at private
hospitals.
Colorectal cancer
For colorectal cancer the geometric mean for time from presenta-
tion to treatment was 138 days (127–152). On univariate analysis,
there were no differences in times from first presentation to
treatment for patients living different distances from cancer
centres (Table 1). Age was important, with fastest treatment for
those in the 50–64 year age group and men were treated more
quickly than women. Again, several organisational variables
Table 1 Time to treatment of breast and colorectal cancer according to geographic, organisational and basic demographic variables
Breast cancer (N¼1069) Colorectal cancer (N¼1071)
N (%) Days – geometric mean (95% CI) P-value
a N (%) Days – geometric mean (95% CI) P-value
a
Distance from cancer centre 0.017 0.361
0–5km 297 (28) 43 (38–47) (0.011) 317 (30) 131 (112–154) (0.248)
6–13 124 (12) 50 (42–60) 123 (12) 170 (135–214)
14–23 135 (13) 51 (43–60) 132 (12) 144 (113–183)
24–37 161 (15) 41 (34–49) 125 (12) 157 (121–204)
38–57 193 (18) 36 (30–42) 193 (18) 138 (110–173)
58+ 159 (15) 40 (34–46) 181 (17) 119 (94–151)
Age group (years) o0.001 0.038
o50 227 (21) 56 (49–65) (o0.001) 53 (5) 182 (129–258) (0.847)
50–64 391 (37) 45 (42–49) 220 (20) 120 (100–145)
65–74 207 (19) 41 (35–47) 570 (53) 132 (116–150)
75+ 244 (23) 29 (26–34) 228 (21) 169 (139–205)
Sex o0.001
Male 590 (55) 117 (104–132)
Female 481 (45) 170 (149–194)
Health board 0.016 NS
A 227 (21) 42 (37–48)
B 381 (36) 47 (42–53)
C 461 (43) 39 (36–42)
Place of presentation o0.001 o0.001
GP 815 (76) 45 (42–49) 1026 (96) 145 (132–159)
Hospital 56 (5) 27 (18–38) 43 (4) 50 (29–84)
Mammogram 197 (18) 36 (33–39)
Hospital referred to o0.001 0.001
Cancer centre 808 (76) 45 (42–48) 577 (54) 126 (111–142)
General 154 (14) 34 (28–41) 277 (26) 133 (110–161)
Community 77 (7) 49 (35–68) 153 (14) 213 (176–258)
Private 22 (2) 22 (15–33) 35 (3) 105 (74–151)
Specialty o0.001 o0.001
Medical 21 (2) 20 (9–44) 266 (25) 215 (185–249)
Surgical 379 (36) 39 (34–44) 787 (74) 121 (109–135)
Breast clinic 650 (61) 46 (43–49) 14 (1)
Other 97 (29–330)
General practice NS
Single handed 59 (6) 208 (151–288) 0.076
2–4 partners 430 (41) 133 (115–153) (0.172)
5–6 partners 396 (37) 146 (126–170)
7+ partners 173 (16) 120 (97–148)
aANOVA association or linear trend for ordered categories in parentheses. There were no differences (P40.10) for categories of deprivation or other general practice factors
(list size, number of female GPs, type of out of hours provision, or waiting time to see GP of choice).
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lappeared to be important, but health board of residence and
deprivation category were not. With regard to symptoms,
treatment was fastest for those with abdominal guarding, and
slowest for those without abdominal pain (Table 4). Increasing
numbers of symptoms and frequency of GP consultations
predicted faster treatment but it was slower for those with a
history of anxiety, depression or benign bowel disease. Tumours of
the transverse colon and splenic flexure were treated more quickly
than other sites.
In the multivariate analysis, there was variation at patient,
practice and health board levels. There was cross-classification
between general practice and hospital levels (patients
from individual practices were referred to different hospitals)
so the hospital level was excluded from the model (hospital
type was included at the health board level). Odds of treatment
within 90 days were higher for those with palpable masses,
abdominal pain or tenesmus, and who consulted more frequently
(Table 5). Age remained significant, following a quadratic
Table 2 Time from presentation to treatment for presenting breast cancer symptoms and other clinical variables
Days from presentation to treatment-geometric mean (95% CI)
N¼1069 Number with symptom (%) With symptom Without symptom P-value
Breast lump 761 (71) 40 (37–43) 49 (44–55) 0.002
Breast pain 106 (10) 69 (54–88) 40 (38–42) o0.001
Nipple discharge – blood 9 (1) 168 (50–567) 42 (39–44) o0.001
Lymphadenopathy (axillary/supraclavicular) 58 (5) 32 (24–41) 43 (40–46) 0.026
Change in skin contour 134 (13) 26 (21–31) 45 (42–48) o0.001
Ulcerating or fungating lesion 26 (2) 17 (9–30) 43 (41–46) o0.001
Lump tethered to skin or underlying tissue 50 (5) 31 (23–42) 43 (40–46) 0.033
Bone pain 7 (1) 15 (6–37) 42 (40–45) 0.008
Skin discolouration 12 (1) 25 (13–48) 42 (40–45) 0.080
Fullness/lumpiness/asymmetry 9 (1) 75 (32–176) 42 (39–45) 0.092
Number of symptoms at presentation o0.001
0 225 (21) 36 (32–40)
1 494 (46) 53 (48–58)
2 248 (23) 37 (33–42)
3 or more 102 (10) 27 (22–34)
Benign investigations in previous 5 years 292 (27) 49 (45–54) 40 (37–43) 0.002
Past history of benign breast disease 220 (21) 55 (46–64) 39 (37–42) o0.001
No differences (P40.10) for nonblood stained nipple discharge, nipple distortion, nipple eczema, breast tenderness, discomfort or itch, breast inflammation, lymphoedema, or
past history of anxiety or depression.
Table 3 Results of multilevel modelling on treatment within 30 days (yes/no) with variation at patient, hospital of referral and health board level for
people with breast cancer
Odds ratio (95% confidence intervals)
a
All referrals
b N¼1097 Referred by GP N¼822
Individual variables
Age at incidence (+10 years) 1.16 (1.05–1.28) 1.12 (0.99–1.26)
No. of symptoms
0 (i.e. screen detected) 11.92 (5.31–26.72)
1 11
2 1.43 (0.95–2.16) 1.62 (1.05–2.51)
3+ 1.97 (1.07–3.64) 2.39 (1.26–4.52)
Breast lump (yes vs no) 3.16 (1.48–6.71) 5.63 (2.20–14.42)
Change in skin contour (yes vs no) 1.71 (1.02–2.85) 1.75 (1.03–2.97)
Lymphadenopathy (yes vs no) 2.05 (1.06–3.99) 2.26 (1.13–4.53)
Hospital variables
Hospital type
Cancer centre 1 1
General 4.18 (2.15–8.13) 5.09 (2.64–9.79)
Community 2.86 (1.45–5.66) 3.63 (1.81–7.28)
Private 13.38 (4.34–41.22) 15.63 (5.09–47.95)
Variation (standard error) at:
Practice level 0.000 (0.000) Practice level 0.000 (0.000)
Hospital level 0.129 (0.096) Hospital level 0.104 (0.094)
Health board level effectively zero Health board level effectively zero
aOdds ratios higher than unity mean higher odds of being treated within 30 days. The values of odds ratios (and their differences from unity) provide an indication of effect sizes.
The magnitude of odds ratios should be interpreted along with the unadjusted means in the previous tables.
bIncludes GP referrals, patients with cancers detected by breast
screening and others.
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lrelationship, meaning treatment was slower for the old and
young. People with a history of anxiety or depression were
only half as likely to be treated within 90 days and those on
iron therapy at presentation were more likely to be treated
quickly. Treatment appeared to be slower for women and faster
for patients registered at practices with higher numbers of
female GPs, although these differences were not statistically
significant.
DISCUSSION
We found no evidence that people living further from cancer
centres received slower treatment. For breast cancer they were, by
being referred initially to local general or community hospitals,
treated more quickly. Speed of treatment appears to be largely
determined by features of the tumour and the symptoms and signs
it generates, but age is important in both cancers, type of hospital
of referral in breast cancer and general practice factors in
colorectal cancer.
The study benefited from a high rate of case note retrieval and
information from primary care, where the majority of cancers
present. Case notes in primary care have the advantage of being
contemporaneous records, but also have some limitations. It is
possible that some symptoms were not recorded at time of
presentation, but our analysis is likely to include the dominant
symptoms and reasons why people consulted. We set strict rules
and protocols for data collection to ensure consistency but must
accept that, for colorectal cancer, it may be difficult to define the
point at which cancer symptoms present in patients with pre-
existing bowel disease. That we did not, after adjustments, find
delays in treatment for this group suggests that any effect from
this, if it occurred, was not substantial. Prospectively, we identified
and collected data on as many variables as possible thought to
affect delay. This had the advantage of ensuring that possible
associations with geographical and organisational factors were not
biased by caseload – and indeed, after adjusting for clinical factors,
most of these associations disappeared – but the disadvantage is
the possibility of some associations emerging by chance. While,
then, we can have confidence in our findings regarding urban rural
differences (our a priori hypothesis), our findings on other factors
would benefit from confirmation in other research.
Our findings demonstrate that clinical factors at presentation –
symptoms, signs, and tumour properties – are the most important
factors in determining time taken before treatment. For breast
cancer, our best fitting model for rapid treatment contained the
usual sign of breast cancer (a lump), one of locally advanced
disease (change in skin contour) and another of regional spread
(axillary or supraclavicular lymphadenopathy). The time taken to
treat colorectal cancer was usually considerably longer than that
for breast cancer – average times to treatment of nearly 5 months
are worrying and could plausibly affect survival (Richards et al,
1999). Delays were associated particularly with the presence or
absence of certain symptoms (e.g. a palpable mass, abdominal pain
Table 4 Time from presentation to treatment for presenting colorectal cancer symptoms and other clinical variables
Days from presentation to treatment-geometric mean (95% CI)
N¼1071 Number with symptom (%) With Without P-value
Abdominal pain 318 (30) 102 (83–125) 158 (144–173) o0.001
Palpable abdominal mass 40 (4) 32 (22–48) 147 (134–160) o0.001
Rectal bleeding 286 (27) 105 (92–120) 153 (137–171) o0.001
Rectal mass 31 (3) 46 (35–59) 143 (131–157) o0.001
Guarding 6 (1) 22 (0.9–540) 140 (128–153) 0.003
Nausea 36 (3) 77 (39–153) 141 (129–155) 0.017
Rectal mucus discharge 47 (4) 85 (60–122) 142 (129–155) 0.023
Tenesmus 29 (3) 76 (49–116) 141 (129–154) 0.028
Increased frequency of bowel movements 67 (6) 99 (72–135) 142 (129–156) 0.057
Abdominal distension 60 (6) 98 (57–170) 141 (129–155) 0.066
Vomiting 83 (8) 105 (65–170) 142 (130–155) 0.083
Number of symptoms at presentation o0.001
0 26 (2) 57 (27–119)
1 459 (43) 208 (184–235)
2 332 (31) 133 (114–156)
3 150 (14) 104 (83–131)
4 or more 104 (10) 49 (36–68)
History of anxiety or depression 143 (13) 210 (167–264) 130 (118–143) o0.001
Past history of benign bowel disease 168 (16) 169 (133–215) 133 (121–147) 0.059
GP consultations/month o0.001
0–0.5 248 (23) 620 (571–673)
0.5–2.5 247 (23) 182 (164–202)
2.5–10 222 (21) 92 (82–105)
410 283 (26) 49 (40–59)
Tumour site 0.072
Right side colon to hepatic flexure 263 (25) 163 (136–197)
Transverse colon to splenic flexure 105 (10) 102 (73–141)
Descending and sigmoid colon 286 (27) 140 (116–170)
Rectosigmoid and rectum 379 (35) 136 (120–154)
Unspecified or overlapping 38 (4) 111 (66–188)
No differences (P40.10) for rectal or anal discomfort, melaena, breathlessness, pallor, tiredness, anaemia, weight loss, anorexia, unspecified changes in bowel habit, urgency,
diarrhoea, constipation, nonspecific anal symptoms, faecal incontinence or discharge, iron medication at time of presentation, or previous benign colorectal investigations.
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lor tenesmus) and frequency of consultation. Tumours of the
transverse colon and splenic flexure were treated more quickly,
perhaps because of a high proportion of splenic flexure tumours
presenting with obstruction (Mulcahy and O’Donoghue, 1997).
Several other factors we found to be related to delay may be
concerned with medical perception of risk. Older people, whose
risk of cancer is greater, were treated more quickly than the under
50s, whose symptoms are less likely to represent cancer
(Selvachandran et al, 2002). In colorectal cancer, the odds of
delayed diagnosis were doubled by a past history of anxiety and
depression, perhaps because benign causes of gastrointestinal
symptoms are thought common in this group so, when presenting
with nonspecific symptoms, their risk of cancer is perceived to be
low. Men with colorectal cancer were treated more quickly than
women, but this difference appears to be largely explained by other
factors because it was no longer significant in the multivariate
model. Faster treatment for those on iron at presentation is odd.
Given our protocols for data collection, this group of patients had
not been anaemic for 2 years, so are likely to have a longstanding
history of iron deficiency. Perhaps, their risk of colorectal cancer
with a given presentation was perceived to be greater – or perhaps
this was a chance finding.
Although average times to treatment of colorectal cancer were
much longer than breast, they were similar when both presented
with a palpable mass. This suggests that much of the delay in
colorectal cancer is related to the nonspecific nature of its early
symptoms and signs (Selvachandran et al, 2002; Tan et al, 2002).
First, there may be reluctance to expose these patients to
investigations that carry a small but significant risk (SIGN,
2003). Second, limited investigative resources in our health care
system mean that rapid investigation and treatment are often only
available for selected patients – deemed ‘urgent’ – and selection is
clearly difficult. In line with this, treatment was faster in the private
sector, where investigations are more readily available – although
the average time saving compared with cancer centres or general
hospitals was only about 3 weeks.
Adjusting for the above factors, we found few associations with
geographical, socioeconomic or organisational variables. At the
population level, neither rural residence nor socioeconomic
deprivation were associated with delays in treatment, so provider
delays do not explain the higher chance of advanced disease
reported for these groups of patients (Macleod et al, 2000;
Campbell et al, 2001). Alternative explanations should be sought,
including the time taken by patients before presentation (Bain and
Campbell, 2000).
Three organisational factors appeared, however, to be impor-
tant. First, breast cancer was treated most quickly if detected by
screening. This appears to show the benefits of a well-organised,
systematic approach to detection and treatment. More than 80% of
people with breast cancer presented outside the screening
programme in our study, and this group might benefit from a
similarly efficient management pathway. Second, adjusting for
clinical factors, treatment delays were more likely for women with
breast cancer referred to cancer centres than other hospitals. This
problem with centralised care has been reported for other cancers
(Milne et al, 2000), but must be balanced against the possible
benefits of specialist treatment (Mikeljevic et al, 2003). Finally,
time to treatment of colorectal cancer varied among general
practices, but this variation was not adequately explained by the
factors we considered. There was a suggestion that treatment may
be faster in practices with more female general practitioners, but
no evidence of systematic differences between practices of different
size or for those with longer waiting times for appointments.
In conclusion, the time taken to treat breast and colorectal
cancers appears to be due largely to characteristics of the tumour
and how it presents. Long delays are common for colorectal
cancer, but we found that time to treatment was no greater for
people with many factors previously suspected to cause delay –
including geographical factors, deprivation and many general
practice factors.
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History of anxiety/depression (yes vs
no)
0.47 (0.28–0.77)
On iron at presentation (yes vs no) 3.77 (1.40–10.12)
Tumour site
Right side colon to hepatic flexure 1
Transverse colon to splenic
flexure
2.27 (1.25–4.12)
Descending and sigmoid colon 1.01 (0.63–1.60)
Rectum and recto-sigmoid 1.40 (0.90–2.18)
Unspecified or overlapping 1.26 (0.58–2.74)
Practice level variables
Number of female GPs (+1) 1.19 (0.99–1.44)
Variation (standard error) at
Health board level 0.045 (0.055)
Practice level 0.048 (0.112)
No significant extra-binomial variation
No significant effect of hospital type at
health board level
aOdds ratio higher than unity means higher odds of being treated within 90 days. For
interpretation of odds ratios see table 3, footnote 1.
bFrequency of consultation
categories: o0.5 consultations per month (from presentation to referral), 0.5–2.5
consultations per month, 2.5–10 consultations per month, 410 consultations per
month.
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